Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

QSI vs ACMR vs ICHR vs PACB

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
QSI
Quantum-Si incorporated

Biotechnology

HealthcareNASDAQ • US
Market Cap$193M
5Y Perf.-90.1%
ACMR
ACM Research, Inc.

Semiconductors

TechnologyNASDAQ • US
Market Cap$3.92B
5Y Perf.+115.0%
ICHR
Ichor Holdings, Ltd.

Semiconductors

TechnologyNASDAQ • US
Market Cap$2.47B
5Y Perf.+123.3%
PACB
Pacific Biosciences of California, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$498M
5Y Perf.-89.6%

QSI vs ACMR vs ICHR vs PACB — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
QSI logoQSI
ACMR logoACMR
ICHR logoICHR
PACB logoPACB
IndustryBiotechnologySemiconductorsSemiconductorsMedical - Devices
Market Cap$193M$3.92B$2.47B$498M
Revenue (TTM)$2M$901M$959M$160M
Net Income (TTM)$-104M$94M$-51M$-546M
Gross Margin-200.5%44.4%11.3%28.2%
Operating Margin-62.1%12.1%-3.8%-346.1%
Forward P/E29.7x62.2x
Total Debt$4M$303M$186M$759M
Cash & Equiv.$22M$766M$98M$64M

QSI vs ACMR vs ICHR vs PACBLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

QSI
ACMR
ICHR
PACB
StockNov 20May 26Return
Quantum-Si incorpor… (QSI)1009.9-90.1%
ACM Research, Inc. (ACMR)100215.0+115.0%
Ichor Holdings, Ltd. (ICHR)100223.3+123.3%
Pacific Biosciences… (PACB)10010.4-89.6%

Price return only. Dividends and distributions are not included.

Quick Verdict: QSI vs ACMR vs ICHR vs PACB

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ACMR leads in 5 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Ichor Holdings, Ltd. is the stronger pick specifically for recent price momentum and sentiment. PACB also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
QSI
Quantum-Si incorporated
The Defensive Pick

QSI is the clearest fit if your priority is sleep-well-at-night.

  • Lower volatility, beta 3.79, Low D/E 1.9%, current ratio 7.64x
Best for: sleep-well-at-night
ACMR
ACM Research, Inc.
The Income Pick

ACMR carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 3 yrs, beta 3.24, yield 0.2%
  • Rev growth 15.2%, EPS growth -10.5%, 3Y rev CAGR 32.3%
  • 30.7% 10Y total return vs ICHR's 6.3%
  • 15.2% revenue growth vs QSI's -20.3%
Best for: income & stability and growth exposure
ICHR
Ichor Holdings, Ltd.
The Momentum Pick

ICHR is the #2 pick in this set and the best alternative if momentum is your priority.

  • +329.1% vs QSI's -18.3%
Best for: momentum
PACB
Pacific Biosciences of California, Inc.
The Defensive Pick

PACB is the clearest fit if your priority is defensive.

  • Beta 2.43, current ratio 6.89x
  • Beta 2.43 vs ICHR's 3.93
Best for: defensive
See the full category breakdown
CategoryWinnerWhy
GrowthACMR logoACMR15.2% revenue growth vs QSI's -20.3%
ValueACMR logoACMRBetter valuation composite
Quality / MarginsACMR logoACMR10.4% margin vs QSI's -56.1%
Stability / SafetyPACB logoPACBBeta 2.43 vs ICHR's 3.93
DividendsACMR logoACMR0.2% yield; 3-year raise streak; the other 3 pay no meaningful dividend
Momentum (1Y)ICHR logoICHR+329.1% vs QSI's -18.3%
Efficiency (ROA)ACMR logoACMR3.9% ROA vs PACB's -66.8%, ROIC 7.0% vs -45.8%

QSI vs ACMR vs ICHR vs PACB — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

QSIQuantum-Si incorporated
FY 2025
Product
93.8%$2M
Service
6.2%$150,000
ACMRACM Research, Inc.
FY 2025
Total Single Wafer and Semi-Critical Cleaning Equipment
69.5%$626M
ECP Front End And Packaging Furnace And Other Technologies
22.1%$200M
Advanced Packaging (exclude ECP), Services & Spares
8.4%$76M
ICHRIchor Holdings, Ltd.

Segment breakdown not available.

PACBPacific Biosciences of California, Inc.
FY 2025
Product
45.9%$136M
Consumable
27.7%$82M
Instrument
18.2%$54M
Service And Other
8.2%$24M

QSI vs ACMR vs ICHR vs PACB — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLACMRLAGGINGPACB

Income & Cash Flow (Last 12 Months)

ACMR leads this category, winning 3 of 6 comparable metrics.

ICHR is the larger business by revenue, generating $959M annually — 518.0x QSI's $2M. ACMR is the more profitable business, keeping 10.4% of every revenue dollar as net income compared to QSI's -56.1%. On growth, PACB holds the edge at +13.8% YoY revenue growth, suggesting stronger near-term business momentum.

MetricQSI logoQSIQuantum-Si incorp…ACMR logoACMRACM Research, Inc.ICHR logoICHRIchor Holdings, L…PACB logoPACBPacific Bioscienc…
RevenueTrailing 12 months$2M$901M$959M$160M
EBITDAEarnings before interest/tax-$112M$126M-$11M-$169M
Net IncomeAfter-tax profit-$104M$94M-$51M-$546M
Free Cash FlowCash after capex-$96M-$69M-$17M-$124M
Gross MarginGross profit ÷ Revenue-2.0%+44.4%+11.3%+28.2%
Operating MarginEBIT ÷ Revenue-62.1%+12.1%-3.8%-3.5%
Net MarginNet income ÷ Revenue-56.1%+10.4%-5.3%-3.4%
FCF MarginFCF ÷ Revenue-51.7%-7.6%-1.7%-77.4%
Rev. Growth (YoY)Latest quarter vs prior year-69.4%+9.4%+4.7%+13.8%
EPS Growth (YoY)Latest quarter vs prior year+9.1%-76.1%+46.2%
ACMR leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

ICHR leads this category, winning 2 of 4 comparable metrics.
MetricQSI logoQSIQuantum-Si incorp…ACMR logoACMRACM Research, Inc.ICHR logoICHRIchor Holdings, L…PACB logoPACBPacific Bioscienc…
Market CapShares × price$193M$3.9B$2.5B$498M
Enterprise ValueMkt cap + debt − cash$175M$3.5B$2.6B$1.2B
Trailing P/EPrice ÷ TTM EPS-1.92x43.21x-46.25x-0.91x
Forward P/EPrice ÷ next-FY EPS est.29.68x62.25x
PEG RatioP/E ÷ EPS growth rate1.22x
EV / EBITDAEnterprise value multiple27.49x
Price / SalesMarket cap ÷ Revenue79.07x4.35x2.61x3.11x
Price / BookPrice ÷ Book value/share0.88x2.06x3.67x92.53x
Price / FCFMarket cap ÷ FCF
ICHR leads this category, winning 2 of 4 comparable metrics.

Profitability & Efficiency

ACMR leads this category, winning 6 of 9 comparable metrics.

ACMR delivers a 6.1% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $-11 for PACB. QSI carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to PACB's 141.98x. On the Piotroski fundamental quality scale (0–9), ICHR scores 3/9 vs ACMR's 2/9, reflecting mixed financial health.

MetricQSI logoQSIQuantum-Si incorp…ACMR logoACMRACM Research, Inc.ICHR logoICHRIchor Holdings, L…PACB logoPACBPacific Bioscienc…
ROE (TTM)Return on equity-47.3%+6.1%-7.5%-11.2%
ROA (TTM)Return on assets-42.7%+3.9%-5.2%-66.8%
ROICReturn on invested capital-38.1%+7.0%-3.9%-45.8%
ROCEReturn on capital employed-42.9%+6.6%-4.7%-58.0%
Piotroski ScoreFundamental quality 0–92233
Debt / EquityFinancial leverage0.02x0.16x0.28x141.98x
Net DebtTotal debt minus cash-$17M-$463M$87M$696M
Cash & Equiv.Liquid assets$22M$766M$98M$64M
Total DebtShort + long-term debt$4M$303M$186M$759M
Interest CoverageEBIT ÷ Interest expense20.44x-5.97x-77.95x
ACMR leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

ACMR leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in ACMR five years ago would be worth $23,344 today (with dividends reinvested), compared to $663 for PACB. Over the past 12 months, ICHR leads with a +329.1% total return vs QSI's -18.3%. The 3-year compound annual growth rate (CAGR) favors ACMR at 80.5% vs PACB's -48.7% — a key indicator of consistent wealth creation.

MetricQSI logoQSIQuantum-Si incorp…ACMR logoACMRACM Research, Inc.ICHR logoICHRIchor Holdings, L…PACB logoPACBPacific Bioscienc…
YTD ReturnYear-to-date-15.5%+31.9%+249.0%-10.3%
1-Year ReturnPast 12 months-18.3%+195.6%+329.1%+46.0%
3-Year ReturnCumulative with dividends-31.9%+487.9%+151.1%-86.5%
5-Year ReturnCumulative with dividends-90.6%+133.4%+28.9%-93.4%
10-Year ReturnCumulative with dividends-90.1%+3065.8%+629.1%-81.3%
CAGR (3Y)Annualised 3-year return-12.0%+80.5%+35.9%-48.7%
ACMR leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — ICHR and PACB each lead in 1 of 2 comparable metrics.

PACB is the less volatile stock with a 2.43 beta — it tends to amplify market swings less than ICHR's 3.93 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ICHR currently trades 97.7% from its 52-week high vs QSI's 31.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricQSI logoQSIQuantum-Si incorp…ACMR logoACMRACM Research, Inc.ICHR logoICHRIchor Holdings, L…PACB logoPACBPacific Bioscienc…
Beta (5Y)Sensitivity to S&P 5003.79x3.24x3.93x2.43x
52-Week HighHighest price in past year$3.10$71.65$72.87$2.73
52-Week LowLowest price in past year$0.69$19.26$13.12$0.85
% of 52W HighCurrent price vs 52-week peak+31.6%+82.6%+97.7%+60.4%
RSI (14)Momentum oscillator 0–10058.960.766.960.2
Avg Volume (50D)Average daily shares traded4.4M1.2M795K5.9M
Evenly matched — ICHR and PACB each lead in 1 of 2 comparable metrics.

Analyst Outlook

ACMR leads this category, winning 1 of 1 comparable metric.

Analyst consensus: QSI as "Buy", ACMR as "Buy", ICHR as "Buy", PACB as "Buy". Consensus price targets imply 2.0% upside for QSI (target: $1) vs -39.4% for PACB (target: $1). ACMR is the only dividend payer here at 0.19% yield — a key consideration for income-focused portfolios.

MetricQSI logoQSIQuantum-Si incorp…ACMR logoACMRACM Research, Inc.ICHR logoICHRIchor Holdings, L…PACB logoPACBPacific Bioscienc…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$1.00$40.00$49.80$1.00
# AnalystsCovering analysts2101418
Dividend YieldAnnual dividend ÷ price+0.2%
Dividend StreakConsecutive years of raises31
Dividend / ShareAnnual DPS$0.11
Buyback YieldShare repurchases ÷ mkt cap0.0%+0.2%0.0%0.0%
ACMR leads this category, winning 1 of 1 comparable metric.
Key Takeaway

ACMR leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ICHR leads in 1 (Valuation Metrics). 1 tied.

Best OverallACM Research, Inc. (ACMR)Leads 4 of 6 categories
Loading custom metrics...

QSI vs ACMR vs ICHR vs PACB: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is QSI or ACMR or ICHR or PACB a better buy right now?

For growth investors, ACM Research, Inc.

(ACMR) is the stronger pick with 15. 2% revenue growth year-over-year, versus -20. 3% for Quantum-Si incorporated (QSI). ACM Research, Inc. (ACMR) offers the better valuation at 43. 2x trailing P/E (29. 7x forward), making it the more compelling value choice. Analysts rate Quantum-Si incorporated (QSI) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — QSI or ACMR or ICHR or PACB?

On forward P/E, ACM Research, Inc.

is actually cheaper at 29. 7x.

03

Which is the better long-term investment — QSI or ACMR or ICHR or PACB?

Over the past 5 years, ACM Research, Inc.

(ACMR) delivered a total return of +133. 4%, compared to -93. 4% for Pacific Biosciences of California, Inc. (PACB). Over 10 years, the gap is even starker: ACMR returned +30. 7% versus QSI's -90. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — QSI or ACMR or ICHR or PACB?

By beta (market sensitivity over 5 years), Pacific Biosciences of California, Inc.

(PACB) is the lower-risk stock at 2. 43β versus Ichor Holdings, Ltd. 's 3. 93β — meaning ICHR is approximately 62% more volatile than PACB relative to the S&P 500. On balance sheet safety, Quantum-Si incorporated (QSI) carries a lower debt/equity ratio of 2% versus 142% for Pacific Biosciences of California, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — QSI or ACMR or ICHR or PACB?

By revenue growth (latest reported year), ACM Research, Inc.

(ACMR) is pulling ahead at 15. 2% versus -20. 3% for Quantum-Si incorporated (QSI). On earnings-per-share growth, the picture is similar: Quantum-Si incorporated grew EPS 28. 2% year-over-year, compared to -140. 6% for Ichor Holdings, Ltd.. Over a 3-year CAGR, ACMR leads at 32. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — QSI or ACMR or ICHR or PACB?

ACM Research, Inc.

(ACMR) is the more profitable company, earning 10. 4% net margin versus -41. 6% for Quantum-Si incorporated — meaning it keeps 10. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACMR leads at 12. 1% versus -39. 8% for QSI. At the gross margin level — before operating expenses — ACMR leads at 44. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is QSI or ACMR or ICHR or PACB more undervalued right now?

On forward earnings alone, ACM Research, Inc.

(ACMR) trades at 29. 7x forward P/E versus 62. 2x for Ichor Holdings, Ltd. — 32. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for QSI: 2. 0% to $1. 00.

08

Which pays a better dividend — QSI or ACMR or ICHR or PACB?

In this comparison, ACMR (0.

2% yield) pays a dividend. QSI, ICHR, PACB do not pay a meaningful dividend and should not be held primarily for income.

09

Is QSI or ACMR or ICHR or PACB better for a retirement portfolio?

For long-horizon retirement investors, Ichor Holdings, Ltd.

(ICHR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+629. 1% 10Y return). Quantum-Si incorporated (QSI) carries a higher beta of 3. 79 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ICHR: +629. 1%, QSI: -90. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between QSI and ACMR and ICHR and PACB?

These companies operate in different sectors (QSI (Healthcare) and ACMR (Technology) and ICHR (Technology) and PACB (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: QSI is a small-cap quality compounder stock; ACMR is a small-cap high-growth stock; ICHR is a small-cap quality compounder stock; PACB is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

QSI

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

ACMR

Steady Growth Compounder

  • Sector: Technology
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 6%
Run This Screen
Stocks Like

ICHR

Quality Business

  • Sector: Technology
  • Market Cap > $100B
Run This Screen
Stocks Like

PACB

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 6%
  • Gross Margin > 16%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform QSI and ACMR and ICHR and PACB on the metrics below

Revenue Growth>
%
(QSI: -69.4% · ACMR: 9.4%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.